Dec 17, 2024 BioXcel Therapeutics Corporate Presentation Apr 10, 2024 Acute Treatment of Agitation Associated with Alzheimer’s Dementia: TRANQUILITY Program Dec 12, 2023 Virtual Neuroscience R&D Day Presentation Oct 10, 2023 BXCL701 / KEYTRUDA® in Small Cell Neuroendocrine Prostate Cancer Jun 29, 2023 Acute Treatment of Agitation in Alzheimer’s Disease: TRANQUILITY II Summary May 25, 2023 SERENITY III Part 1 Topline Results Mar 02, 2023 Novel Treatment for Agitation in Neuropsychiatric Conditions Feb 21, 2023 BXCL701 KOL Day Presentation Feb 13, 2023 BXCL701 Full Data Results From Phase 2 Trial in Rare, Aggressive Form of Prostate Cancer—SCNC Jan 11, 2023 41th Annual J.P. Morgan Healthcare Conference Presentation Oct 18, 2022 IGALMI Commercial Day Presentation Apr 06, 2022 IGALMI™ Approval Presentation Sep 23, 2021 R&D Day Mar 03, 2021 Phase 1b/2 TRANQUILITY Trial – Program Update Jul 20, 2020 SERENITY I & II Phase 3 Trials Topline Results
Feb 13, 2023 BXCL701 Full Data Results From Phase 2 Trial in Rare, Aggressive Form of Prostate Cancer—SCNC
